Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives.

Autores de IIS La Fe

• Gladys Guadalupe Olivera Pasquini

  Autor

Participantes ajenos a IIS La Fe

• Apellaniz-Ruiz, Maria
• Barrachina, Jordi
• Castro-Sanchez, Paula
• Comes-Raga, Ana
• Garcia-Gonzalez, Xandra
• Gil-Rodriguez, Almudena
• Lopez-Lopez, Elixabet
• Maronas, Olalla
• Moron, Rocio
• Muriel, Javier
• Riera, Pau
• Saiz-Rodriguez, Miriam
• Salvador-Martin, Sara
• Sans-Pola, Carla
• Tejera-Perez, Hugo
• Velasco-Ruiz, Alejandro
• Verde, Zoraida
• Wang, Daniel
• Rodriguez-Vicente, Ana E
• Nunez-Torres, Rocio
• Junior Group of the Spanish Society of Pharmacogenetics and
• Pharmacogenomics

Grupos

• Farmacogenética

Abstract

INTRODUCTION: Pharmacogenetics (PGx) has the potential to improve patient care, allowing to transform medical interventions by providing personalized therapeutic strategies. Scientific evidence supports the use of PGx in clinical practice and international organizations are developing clinical guidelines to facilitate the utilization of PGx testing. However, clinical implementation of PGx is limited and unequal worldwide. CONTENT: This review summarizes regional and national Spanish initiatives to implement PGx in the clinical practice. SUMMARY AND OUTLOOK: Diverse strategies to implement PGx in healthcare are applied across countries or even in the different regions of a specific country. Such was the case of Spain, a European country with 17 Autonomous Regions and two Autonomous Cities, each one with capacity to manage their own healthcare systems. Nevertheless, during the past years, many initiatives and strategies have been launched in Spain to develop different aspects of PGx. Importantly, the National Healthcare System has approved a PGx testing catalogue. This review highlights the crucial work and efforts of scientific societies (like the Spanish Society of Pharmacogenetics and Pharmacogenomics), of experts in PGx, of healthcare providers and of governmental parties in the implementation of PGx to personalize patient therapy, focused in Spain.